Stroke in Heart Failure in Sinus Rhythm: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction Trial | Zendy

Patrick M. Pullicino | Zendy; John L.P. Thompson | Zendy; Ralph L. Sacco | Zendy; Alexandra Sanford | Zendy; Min Qian | Zendy; John R. Teerlink | Zendy; Haissam Haddad | Zendy; Monika Diek | Zendy; Ronald S. Freudenberger | Zendy; Arthur J. Labovitz | Zendy; Marco R. Di Tullio | Zendy; Dirk J. Lok | Zendy; Piotr Ponikowski | Zendy; Stefan D. Anker | Zendy; Susan Graham | Zendy; Douglas L. Mann | Zendy; J.P. Mohr | Zendy; Shunichi Homma | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Stroke in Heart Failure in Sinus Rhythm: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction Trial

Author(s) -

Patrick M. Pullicino,

John L.P. Thompson,

Ralph L. Sacco,

Alexandra Sanford,

Min Qian,

John R. Teerlink,

Haissam Haddad,

Monika Diek,

Ronald S. Freudenberger,

Arthur J. Labovitz,

Marco R. Di Tullio,

Dirk J. Lok,

Piotr Ponikowski,

Stefan D. Anker,

Susan Graham,

Douglas L. Mann,

J.P. Mohr,

Shunichi Homma

Publication year - 2013

Publication title -

cerebrovascular diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.221

H-Index - 104

eISSN - 1421-9786

pISSN - 1015-9770

DOI - 10.1159/000352058

Subject(s) - medicine , warfarin , atrial fibrillation , aspirin , ejection fraction , stroke (engine) , cardiology , sinus rhythm , heart failure , modified rankin scale , anesthesia , ischemic stroke , ischemia , mechanical engineering , engineering

The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths. Prespecified secondary analysis showed a 48% hazard ratio reduction (p = 0.005) for warfarin in IIS. Cardioembolism is likely the main pathogenesis of stroke in heart failure. We examined the IIS benefit for warfarin in more detail in post hoc secondary analyses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research